Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 28 articles:
HTML format
Text format



Single Articles


    June 2017
  1. CARBONE DP, Reck M, Paz-Ares L, Creelan B, et al
    First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:2415-2426.
    PubMed     Text format     Abstract available


  2. PETERS S, Camidge DR, Shaw AT, Gadgeel S, et al
    Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Jun 6. doi: 10.1056/NEJMoa1704795.
    PubMed     Text format     Abstract available


  3. ROBLES AI, Zenklusen JC
    Seeing the Forest through the Phylogenetic Tree.
    N Engl J Med. 2017;376:2190-2191.
    PubMed     Text format    


    May 2017
  4. NISHINO M, Hatabu H
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1992-3.
    PubMed     Text format    


  5. YIN Y, Li J
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993.
    PubMed     Text format    



  6. Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993-4.
    PubMed     Text format    


  7. ZHANG BM, Aleshin A, Lin CY, Ford J, et al
    IDH2 Mutation in a Patient with Metastatic Colon Cancer.
    N Engl J Med. 2017;376:1991-2.
    PubMed     Text format    


    April 2017
  8. JAMAL-HANJANI M, Wilson GA, McGranahan N, Birkbak NJ, et al
    Tracking the Evolution of Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Apr 26. doi: 10.1056/NEJMoa1616288.
    PubMed     Text format     Abstract available


    March 2017
  9. DEFILIPPIS EM, Vaidya A, Ramani S, French C, et al
    Under Pressure.
    N Engl J Med. 2017;376:e23.
    PubMed     Text format    


  10. SORSCHER S
    Pembrolizumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:996-7.
    PubMed     Text format    



  11. Pembrolizumab in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:997.
    PubMed     Text format    


    February 2017
  12. MAOZ A, Rennert G, Gruber SB
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    


  13. RECH AJ, Vonderheide RH
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    


  14. ROSENBERG SA, Tran E, Robbins PF
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    


  15. MOK TS, Wu YL, Ahn MJ, Garassino MC, et al
    Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:629-640.
    PubMed     Text format     Abstract available


    December 2016
  16. TRAN E, Robbins PF, Lu YC, Prickett TD, et al
    T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
    N Engl J Med. 2016;375:2255-2262.
    PubMed     Text format     Abstract available


    October 2016
  17. JOHNSON BE
    Divide and Conquer to Treat Lung Cancer.
    N Engl J Med. 2016.
    PubMed     Text format    


  18. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


    August 2016
  19. CHOY E, Hornicek FJ, Chen YL, Rosenthal DI, et al
    CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 26-2016. A 28-Year-Old Woman with Back Pain and a Lesion in the Lumbar Spine.
    N Engl J Med. 2016;375:779-88.
    PubMed     Text format    


    July 2016
  20. POLLARD JW
    Defining Metastatic Cell Latency.
    N Engl J Med. 2016;375:280-2.
    PubMed     Text format    


    June 2016
  21. SEQUIST LV, Soria JC, Camidge DR
    Update to Rociletinib Data with the RECIST Confirmed Response Rate.
    N Engl J Med. 2016;374:2296-7.
    PubMed     Text format    


    May 2016
  22. SWANTON C, Govindan R
    Clinical Implications of Genomic Discoveries in Lung Cancer.
    N Engl J Med. 2016;374:1864-73.
    PubMed     Text format    


  23. BORDI P, Del Re M, Tiseo M
    Crizotinib Resensitization by Compound Mutation.
    N Engl J Med. 2016;374:1790.
    PubMed     Text format    


  24. SHAW AT, Engelman JA
    Crizotinib Resensitization by Compound Mutation.
    N Engl J Med. 2016;374:1790-1.
    PubMed     Text format    


    February 2016
  25. GYAWALI B, Ota A, Ando Y
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:493.
    PubMed     Text format    


  26. HASEGAWA T, Uno H, Wei LJ
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:492-3.
    PubMed     Text format    


  27. BORGHAEI H, Brahmer J
    Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016;374:493-4.
    PubMed     Text format    


    January 2016
  28. SHAW AT, Friboulet L, Leshchiner I, Gainor JF, et al
    Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    N Engl J Med. 2016;374:54-61.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: